RxDoctor Payments Data

Luis Pena Figueroa, MD

General Practice · Dorado, PRNPI 1982688776

Payments from drug & device makers

$2,179in general payments, 2019–2025

Across 60 payments — averaging $36.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$635
  • AstraZeneca$601
  • Johnson & Johnson$364
  • Novo Nordisk$135
  • GSK$125
  • Pfizer Pharmaceuticals LLC$120
  • plus $199 from 4 others

What the payments were for

  • Food & beverage$2,16799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie25$635
AstraZeneca9$601
Johnson & Johnson8$364
Novo Nordisk6$135
GSK1$125
Pfizer Pharmaceuticals LLC2$120
E.r. Squibb & Sons, L.L.C.3$59
Merck3$58
PBG Puerto Rico LLC2$50
Genentech USA, Inc.1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,179 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,967
Medicare patients
23
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$88,795
XareltoRivaroxaban94$63,437
FarxigaDapagliflozin Propanediol63$47,028
Trijardy XrEmpaglifloz/Linaglip/Metformin34$38,184
SynthroidLevothyroxine Sodium618$38,051
JardianceEmpagliflozin23$35,558
OzempicSemaglutide22$21,401
TradjentaLinagliptin25$21,061
LantusInsulin Glargine,hum.Rec.Anlog159$17,136
Atorvastatin Calcium996$11,964
Gabapentin1,410$11,587
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$10,193
Diclofenac Potassium322$8,711
Xigduo XrDapaglifloz Propaned/Metformin14$8,533
Levothyroxine Sodium778$8,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$364$63,43794 claims
AstraZenecaFarxiga, Brilinta$601$51,80374 claims
AbbVieSynthroid, Lumigan$635$42,593632 claims
Novo NordiskOzempic$135$21,40122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Dorado

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →